Cleantech Innovator BioLargo Reports Record Revenues in 2024 Annual Report
BioLargo (OTCQX:BLGO) reported record-breaking financial results for 2024, marking its tenth consecutive year of revenue growth. The cleantech company achieved revenues of $17.77 million, representing a 45% increase from 2023. The company's net loss decreased by 6% to $4.34 million, with $3.49 million attributed to Clyra Medical operations.
The company's financial position showed improvement with $3.54 million in cash, total assets of $10.51 million, and stockholders' equity of $6.05 million. BioLargo reduced its reliance on equity financing, issuing 42% fewer shares compared to 2023. The company generated over $5 million from odor control products and continues to develop emerging technologies, including Clyra surgical products, PFAS water treatment solutions, and Cellinity battery storage technology.
BioLargo (OTCQX:BLGO) ha riportato risultati finanziari da record per il 2024, segnando il suo decimo anno consecutivo di crescita dei ricavi. L'azienda cleantech ha raggiunto ricavi di 17,77 milioni di dollari, con un aumento del 45% rispetto al 2023. La perdita netta dell'azienda è diminuita del 6% a 4,34 milioni di dollari, con 3,49 milioni attribuiti alle operazioni di Clyra Medical.
La posizione finanziaria dell'azienda ha mostrato miglioramenti con 3,54 milioni di dollari in contante, attivi totali di 10,51 milioni di dollari e un patrimonio netto di 6,05 milioni di dollari. BioLargo ha ridotto la sua dipendenza dal finanziamento tramite capitale, emettendo il 42% di azioni in meno rispetto al 2023. L'azienda ha generato oltre 5 milioni di dollari da prodotti per il controllo degli odori e continua a sviluppare tecnologie emergenti, inclusi i prodotti chirurgici Clyra, soluzioni per il trattamento dell'acqua PFAS e la tecnologia di stoccaggio delle batterie Cellinity.
BioLargo (OTCQX:BLGO) reportó resultados financieros récord para 2024, marcando su décimo año consecutivo de crecimiento en ingresos. La empresa de cleantech alcanzó ingresos de 17,77 millones de dólares, lo que representa un incremento del 45% en comparación con 2023. La pérdida neta de la empresa disminuyó un 6% a 4,34 millones de dólares, con 3,49 millones atribuidos a las operaciones de Clyra Medical.
La posición financiera de la empresa mostró mejoras con 3,54 millones de dólares en efectivo, activos totales de 10,51 millones de dólares y un patrimonio neto de 6,05 millones de dólares. BioLargo redujo su dependencia de financiamiento mediante capital, emitiendo un 42% menos de acciones en comparación con 2023. La empresa generó más de 5 millones de dólares de productos para el control de olores y continúa desarrollando tecnologías emergentes, incluidos los productos quirúrgicos Clyra, soluciones de tratamiento de agua PFAS y la tecnología de almacenamiento de baterías Cellinity.
BioLargo (OTCQX:BLGO)는 2024년 기록적인 재무 결과를 보고하며 10년 연속 매출 성장을 기록했습니다. 이 클린테크 기업은
회사의 재무 상태는 354만 달러의 현금, 총 자산 1051만 달러, 주주 자본 605만 달러로 개선되었습니다. BioLargo는 자본 조달에 대한 의존도를 줄여 2023년 대비 42% 적은 주식을 발행했습니다. 이 회사는 악취 제어 제품에서 500만 달러 이상을 창출했으며, Clyra 외과 제품, PFAS 수처리 솔루션 및 Cellinity 배터리 저장 기술을 포함한 신기술 개발을 지속하고 있습니다.
BioLargo (OTCQX:BLGO) a annoncé des résultats financiers records pour 2024, marquant sa dixième année consécutive de croissance des revenus. L'entreprise cleantech a réalisé des revenus de 17,77 millions de dollars, représentant une augmentation de 45% par rapport à 2023. La perte nette de l'entreprise a diminué de 6% pour atteindre 4,34 millions de dollars, dont 3,49 millions de dollars attribués aux opérations de Clyra Medical.
La situation financière de l'entreprise a montré une amélioration avec 3,54 millions de dollars en liquidités, des actifs totaux de 10,51 millions de dollars et des capitaux propres de 6,05 millions de dollars. BioLargo a réduit sa dépendance au financement par actions, émettant 42% d'actions en moins par rapport à 2023. L'entreprise a généré plus de 5 millions de dollars grâce à des produits de contrôle des odeurs et continue de développer des technologies émergentes, y compris des produits chirurgicaux Clyra, des solutions de traitement des eaux PFAS et la technologie de stockage de batteries Cellinity.
BioLargo (OTCQX:BLGO) hat für 2024 Rekordfinanzergebnisse gemeldet und damit das zehnte Jahr in Folge ein Umsatzwachstum erzielt. Das Cleantech-Unternehmen erzielte Umsätze von 17,77 Millionen Dollar, was einem 45%igen Anstieg im Vergleich zu 2023 entspricht. Der Nettoverlust des Unternehmens sank um 6% auf 4,34 Millionen Dollar, wobei 3,49 Millionen Dollar auf die Aktivitäten von Clyra Medical zurückzuführen sind.
Die finanzielle Lage des Unternehmens verbesserte sich mit 3,54 Millionen Dollar in bar, Gesamtvermögen von 10,51 Millionen Dollar und Eigenkapital von 6,05 Millionen Dollar. BioLargo reduzierte seine Abhängigkeit von Eigenkapitalfinanzierungen und gab 42% weniger Aktien im Vergleich zu 2023 aus. Das Unternehmen erzielte über 5 Millionen Dollar aus Produkten zur Geruchskontrolle und entwickelt weiterhin aufkommende Technologien, einschließlich Clyra-Chirurgieprodukte, PFAS-Wasseraufbereitungslösungen und Cellinity-Batteriespeichertechnologie.
- Record revenue of $17.77 million, up 45% year-over-year
- Tenth consecutive year of revenue growth
- 6% reduction in net loss
- Generated over $5 million from odor control products
- 42% reduction in share issuance, decreasing dilution
- Strong balance sheet with $3.54 million cash position
- Net loss of $4.34 million despite revenue growth
- Significant losses ($3.49 million) from Clyra Medical operations
- Non-cash expenses of $2.47 million from stock and options issuance
Revenues up
WESTMINSTER, CALIFORNIA / ACCESS Newswire / April 1, 2025 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its Annual Report reported record revenues and an increase of
"We're proud to report the tenth year in a row of record revenues in our 10-K filed yesterday," said Dennis P. Calvert, the company's President and CEO. "With over
BioLargo held an earnings webcast and conference call on March 31, 2025, to discuss results for the year ended December 31, 2024. A recording and transcript of this webcast will be made available at the following link: https://www.biolargo.com/quarterly-webcasts
The following are highlights from BioLargo's annual report filed with the Securities and Exchange Commission (SEC) on March 31, 2025, and are not a substitute for the details in the Form 10-K, which can be found here (https://www.biolargo.com/sec-filings). All interested parties are encouraged to review the full report filed with the SEC, including the Risk Factors beginning on page 9, to get the most complete information about BioLargo and its growing cleantech business.
Key highlights:
Revenues for the year ended December 31, 2024, were
$17,779,000 , a45% increase over 2023, which represents the tenth consecutive year of revenue growthNet loss for 2024 was
$4,347,000 , a6% decrease year-over-year; of that amount,$3,490,000 was from Clyra Medical's operationsClyra Medical continues to make progress towards a national rollout of its surgical irrigation products, recently successfully concluding a joint formal inspection of manufacturing capabilities with its distribution partner
Non-cash expenses (issuance of stock and stock options) were
$2,479,000 (57% of net loss)Company was less reliant on equity financing in 2024, issuing
42% fewer shares of stock in 2024 as compared with 2023At December 31, 2024, stockholders' equity was
$6,056,000 , assets were$10,513,000 , liabilities were$4,457,000 , and the company had$4,489,000 in working capital and$3,548,000 in cash and cash equivalents
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc
View the original press release on ACCESS Newswire
FAQ
What was BioLargo's (BLGO) revenue growth in 2024?
How much did BioLargo (BLGO) reduce its net loss in 2024?
What is BioLargo's (BLGO) cash position as of December 31, 2024?
How did BioLargo (BLGO) reduce its equity financing in 2024?
What was BioLargo's (BLGO) stockholders' equity in 2024?
